Sonnet BioTherapeutics Holdings, Inc. (SONN)
SONN moved a median of -1.40% 30 minutes after news, and -1.72% by the close. How SONN actually reacts to news — the realized, point-in-time move the market made, measured across 246 labeled events over the last three years with zero look-ahead.
SONN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 184 |
| 30-min | -1.40% | 28% | 189 |
| 60-min | -1.19% | 35% | 190 |
| to close | -1.72% | 40% | 189 |
| Middle 50% of SONN reactions | -5.24% to +0.61% |
|---|---|
| Median reaction (30-min) | -1.40% |
| Measured reactions | 246 |
Half of all Sonnet BioTherapeutics Holdings, Inc. news events land between -5.24% and +0.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SONN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SONN's baseline. Nothing else.
Recent SONN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-1 Hyperliquid Strategies | SEC filing · Form S-1 | SEC EDGAR | — | — | |
| Form S-8 Hyperliquid Strategies | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-Q Hyperliquid Strategies For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Hyperliquid Strategies For: May 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K/A Hyperliquid Strategies For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Hyperliquid Strategies For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Hyperliquid Strategies For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Sonnet BioTherapeutics | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Sonnet BioTherapeutics | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Sonnet BioTherapeutics For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Sonnet BioTherapeutics For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | -13.29% | -60.13% | |
| Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination | Press release | GlobeNewswire | — | — | |
| Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc | Press release | GlobeNewswire | -13.29% | -60.13% | |
| Form 8-K Sonnet BioTherapeutics For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -5.42% | |
| Form DEFA14A Sonnet BioTherapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.19% | -5.42% | |
| Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting | Press release | GlobeNewswire | +0.19% | -5.42% | |
| Form DEFM14A Sonnet BioTherapeutics | SEC filing · Form DEFM14A | SEC EDGAR | +1.24% | -13.30% | |
| Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma | Press release | GlobeNewswire | -1.52% | -10.22% | |
| Form 8-K Sonnet BioTherapeutics For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | +0.62% | -5.57% | |
| Sonnet to Present at the MedInvest Biotech & Pharma Conference | Press release | GlobeNewswire | -2.62% | -14.37% | |
| Form ARS Sonnet BioTherapeutics For: Sep 30 | SEC filing · Form ARS | SEC EDGAR | -1.44% | -6.58% | |
| Form DEF 14A Sonnet BioTherapeutics For: Aug 26 | SEC filing · Form DEF | SEC EDGAR | -1.44% | -6.58% | |
| Form 10-Q Sonnet BioTherapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +9.85% | +7.43% | |
| Sonnet Releases Virtual Investor "What This Means" Segment | Press release | GlobeNewswire | +3.15% | -9.44% | |
| Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer | Press release | GlobeNewswire | -3.31% | -2.09% | |
| Form 8-K Sonnet BioTherapeutics For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -3.31% | -2.09% | |
| Form 8-K Sonnet BioTherapeutics For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +1.25% | |
| Form 8-K Sonnet BioTherapeutics For: Jul 18 | SEC filing · Form 8-K | SEC EDGAR | -0.16% | -17.07% | |
| Form 8-K Sonnet BioTherapeutics For: Jul 11 | SEC filing · Form 8-K | SEC EDGAR | +12.73% | -35.73% | |
| SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | +12.73% | -35.73% | |
| Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy | Press release | GlobeNewswire | +12.73% | -35.73% | |
| Form 8-K Sonnet BioTherapeutics For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +3.08% | — | |
| Form 8-K Sonnet BioTherapeutics For: May 30 | SEC filing · Form 8-K | SEC EDGAR | — | -1.09% | |
| Form 10-Q Sonnet BioTherapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -3.01% | |
| Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit | Press release | GlobeNewswire | -0.71% | -0.71% | |
| Sonnet Releases Virtual Investor "What This Means" Segment | Press release | GlobeNewswire | -0.65% | -4.65% | |
| Form 8-K Sonnet BioTherapeutics For: Apr 04 | SEC filing · Form 8-K | SEC EDGAR | -23.23% | -26.47% | |
| Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose | Press release | GlobeNewswire | -23.23% | -26.47% | |
| Form 8-K Sonnet BioTherapeutics For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +4.80% | |
| Sonnet Announces Release of Corporate Update Video | Press release | GlobeNewswire | +0.80% | +4.80% | |
| Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. | Press release | GlobeNewswire | -3.91% | -0.78% | |
| Form 8-K Sonnet BioTherapeutics For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.00% | |
| Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas | Press release | GlobeNewswire | +0.00% | -5.00% | |
| Form 8-K Sonnet BioTherapeutics For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +1.80% | +0.72% | |
| Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein | Press release | GlobeNewswire | +1.80% | +0.72% | |
| Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference | Press release | GlobeNewswire | +1.22% | -1.42% | |
| Form 8-K Sonnet BioTherapeutics For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.66% | |
| Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors | Press release | GlobeNewswire | +0.00% | +0.66% | |
| Form 8-K Sonnet BioTherapeutics For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -3.20% | +0.00% | |
| Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates | Press release | GlobeNewswire | -3.20% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SONN section they belong to.
Where else SONN is measured.
SONN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sonnet BioTherapeutics Holdings, Inc.'s median reaction calculated?
Every labeled SONN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 246 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 28% of SONN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SONN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.